StockData

Abeona Therapeutics vs Aquestive Therapeutics

ABEO and AQST side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ABEO and AQST compare

Aquestive Therapeutics is the larger company, worth 3.1 times as much as Abeona Therapeutics ($464M against $149M).

Aquestive Therapeutics keeps more of each dollar of sales as profit, with a net margin of −145% compared with −246% at Abeona Therapeutics.

Abeona Therapeutics scores higher on the StockData Score (8 against 3 for Aquestive Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricABEOAQST
Size and price
Market cap$149M$464M
Share price$2.60$3.70
Change, 1 year−41.6%−31.4%
Change, 5 years−85.8%−41.9%
Beta (5Y)1.711.20
Employees226147
StockData Score
Total score8 (better)3
Valuation score3 (better)0
Growth score12 (better)
Performance score2 (better)0
Health score2 (better)1
Dividend score00
Valuation
P/S5.8× (better)8.6×
P/B1.2×–
FCF yield−54.8%−9.9% (better)
Fair value$3.58–
Margin of safety27.4%–
Growth
Revenue growth (TTM)–22.6%
Revenue growth, 5Y average−10.3%−0.58% (better)
Net income growth (TTM)−210%–
Profitability
Gross margin67.1% (better)67.0%
Operating margin−328%−97.5% (better)
Net margin−246%−145% (better)
FCF margin−319%−85.0% (better)
Return on equity−43.1%–
Financial health
Debt / equity0.12–
Interest coverage−25.3×−4.7× (better)
Current ratio6.637.19 (better)
Altman Z-score−4.80−3.57 (better)
Piotroski F-score4 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions77.9%57.4%
Held by insiders12.3%3.2%
Insider net buying, 12 months−$3.5M−$2.3M (better)
Short interest, % of float33.7%24.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.